

Low-Energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial

¹Tony Realini, MD, MPH, ²Gus Gazzard, MD, ³Mark Latina, MD, and ⁴Michael Kass, MD

1. Department of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, WV

2. NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK;
University College London, UK

3. Department of Ophthalmology, Tufts University, Boston, MA

4. Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO

Correspondence to:

Tony Realini, MD, MPH

1 Medical Center Drive

Box 9193

Morgantown, WV 26506

Ph: (304) 598-6926

Fax: (304) 598-6928

Email: realinia@wvumedicine.org

Supported by National Eye Institute/National Institutes of Health grants UG1 EY031654 and UG1 EY031651.

Disclosure: The authors declare no conflict of interest.

At the 2018 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Stephano Gandolfi presented a retrospective study of his patients at the University of Parma, Italy, in which a regimen of low-energy selective laser trabeculoplasty (SLT) repeated annually irrespective of intraocular pressure (IOP) produced significantly longer medication-free survival than standard SLT repeated as needed, in patients with primary open-angle glaucoma (POAG) or high-risk ocular hypertension (OHTN).¹ Specifically, newly-diagnosed POAG eyes were treated primarily either with ALT 360° performed once, standard SLT 360° repeated as needed at standard energy, and low-energy 360° SLT (0.4 mJ/spot x 50-60 spots) repeated annually at low energy regardless of IOP. After 10 years of follow-up, medication-free rates were 22.6% in the ALT group, 25.0% in the standard SLT group, and 58.3% in the low-energy SLT group ($p < 0.001$). The median times to medication were 2.8 years, 3.2 years, and 6.2 years, respectively. In light of the recent Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) publication, in which primary SLT was shown to be at least as effective as medical therapy in newly-diagnosed and treatment naïve patients with mild-moderate POAG or high-risk OHTN and the likelihood of a paradigm shift toward a laser-first regimen, Gandolfi's data suggested that the long-term utility of SLT in glaucoma management may be improvable by altering the energy level and frequency at which SLT is performed. These intriguing observations led us to conduct a comprehensive review of the SLT literature in search of a basis for the biological plausibility of such an approach. The results of that literature review, summarized herein, prompted application to the National Eye Institute (NEI) at the National Institutes of Health for funding to conduct a pair of multicenter randomized trials to evaluate outcomes of SLT performed annually at low energy. These trials—collectively named the Clarifying the Optimal Application of SLT Therapy (COAST) trial—were funded in late 2020 by NEI to compare standard versus low-energy primary SLT and annual versus pro re nata (PRN) repeat SLT and are currently in the pre-enrollment phase. In this report, we share the background and rationale that informed the design of the COAST trial.

The Glaucoma Treatment Paradigm Is Overdue For Reconsideration

Past. The therapeutic approach to POAG is the reduction of intraocular pressure (IOP). The traditional approach to IOP reduction utilizes topical medications first, followed if needed by laser therapy and then incisional surgery. This historical strategy, based on the Hippocratic principle of doing no harm, reflects an era of surgical options with significant sight-threatening adverse events and a laser procedure (argon laser trabeculoplasty [ALT]) that wore off over time, was generally less effective with repeat treatment, and was not generally considered safe to repeat,² thus limiting its role in long-term disease management.

Present. The therapeutic landscape for glaucoma has changed significantly since the establishment of the medication-first paradigm, and the glaucoma treatment paradigm is overdue for an update that reflects the modern body of knowledge regarding contemporary IOP-lowering options. The advent of minimally invasive glaucoma surgeries (MIGS) has significantly improved the safety profile of incisional glaucoma surgery and expanded its applicability to a broader spectrum of glaucoma patients.³⁻⁷ The development of SLT and the establishment of its safe and effective repeatability when its effect wanes⁸⁻¹⁶ offer an alternative to medical therapy for first-line application and long-term disease management. And while modern glaucoma medications offer superior efficacy and safety to older drugs, a wealth of research over the past 2 decades has demonstrated that the efficacy of medical therapy established in clinical trials does not translate to real-world effectiveness due to widespread non-adherence. In fact, therapeutic non-adherence may be the single biggest limitation of topical medical therapy. Poor adherence has been well documented to be common among glaucoma patients and is a complex, multifactorial behavior that is not easily identified or overcome.¹⁷⁻²³

In addition to poor adherence, medical therapy for glaucoma has other limitations. Many patients require more than 1 medication to achieve IOP control. In the Ocular Hypertension Treatment Study (OHTS), nearly half of patients required 2 or more medications to achieve a modest 20% IOP reduction.²⁴ In the SLT-MED study, 27% of eyes randomized to the medication-first group required 2+ medications within 1 year when treated to target IOP.²⁵ Multi-drug glaucoma regimens are also linked to reductions in quality of life,²⁶⁻²⁹ the preservation of which is the ultimate goal of glaucoma therapy.^{30,31} Contributing to the

negative impact on quality of life are the side effects of topical medical therapy, which range from cosmetic nuisances to severe adverse events. Topical medications—potentially related to their preservative ingredients—also contribute to high rates of ocular surface disease among glaucoma patients,^{32,33} and subclinical ocular surface inflammation can reduce the success of subsequent filtration surgery.³⁴ The cost of medical therapy is often borne at least in part by patients and can be substantial for the un- or under-insured. Side effects and cost likely contribute in part to nonadherence.

Future. Primary SLT overcomes many of the imitations of the medication-first paradigm. Foremost, SLT eliminates the issue of nonadherence by obviating the need for daily self-dosing by patients. SLT can also reduce the medication burden, thus reducing multi-drug regimens and their detrimental effects on the ocular surface and quality of life. In SLT-MED, 0% of eyes treated with primary SLT required any medications at 12 months compared to 100% requiring 1+ medications and 27% requiring 2+ medications.²⁵ In the Laser in Glaucoma and Ocular Hypertension (LiGHT) study, 78% of SLT-first eyes versus only 3% of medication-first eyes were medication-free at 3 years.¹⁶ Further, SLT is more cost-effective than medical therapy for glaucoma.^{16,35,36} These benefits come with no efficacy costs. SLT provides IOP-lowering efficacy comparable to a prostaglandin analogue, the preferred first-line medication for glaucoma.^{16,25,37,38} SLT provides mean IOP reductions on the order of 6-8 mmHg (25-30%),^{16,25,37,38} consistent with the guidelines for initial IOP reduction for most eyes with early or moderate POAG.^{30,31} SLT's efficacy has also been established in people of African descent,³⁹⁻⁴³ where POAG has the highest prevalence and glaucoma-related blindness is most common.^{44,45} While SLT's effect on IOP dissipates over time, most eyes will remain controlled after a single SLT treatment for 3-5 years,^{16,46} and repeat SLT consistently and safely restores IOP control to levels achieved by initial SLT.⁸⁻¹⁶ Further, the safety profile of SLT is at least as favorable as prostaglandin therapy, and unlike with medical therapy, side effects of SLT are generally transient and self-limited, resolving within 3-5 days post-treatment.^{47,48}

The Paradigm Shift

Several studies have evaluated the role of primary trabeculoplasty for POAG. The landmark Glaucoma Laser Trial (GLT) demonstrated better IOP control (albeit potentially related to crossover effect from timolol therapy to the contralateral eye) and less visual field and optic nerve progression in eyes treated with ALT first compared to medications first through up to 9 years of follow-up.² This seminal study did not drive a paradigm shift to laser first, likely due to the fact that most laser-first eyes required medications over time as ALT was not felt to be safely repeatable (see below).

ALT has largely been supplanted by SLT, which has a similar efficacy profile but is performed with far less energy.⁴⁹⁻⁵⁵ The SLT-MED study compared SLT-first and medication (prostaglandin)-first treatment strategies in newly-diagnosed and treatment naïve POAG eyes. The study was terminated early due to enrollment issues, and while the final data set was underpowered to compare the two treatments, the mean IOP reduction in the two groups was arithmetically similar (6.3 mmHg for SLT and 7.0 mmHg for medications).²⁵ Unsurprisingly, this underpowered study also failed to drive the paradigm from medications to laser.

More recently, in the landmark LiGHT study,^{16,56} 718 newly-diagnosed and treatment-naïve POAG patients were assigned to therapy with SLT or medications. Eyes in the SLT arm received SLT, repeat SLT, and then medications to achieve target IOP, while eyes in the medication arm received sequentially added medications to achieve target IOP. At the 3-year time point, mean IOP was similar between groups, but glaucoma progression was more common in the medication group (10.0% versus 6.4%) and all 11 trabeculectomy procedures in the study occurred in the medication arm. Medication-free disease control in the SLT arm (allowing for 1 repeat SLT as needed) was achieved by 85.2%, 79.2%, and 74.6% of eyes at 1, 2 and 3 years, respectively. Also, a slightly larger proportion of eyes treated with medication demonstrated rapid visual field progression compared to SLT-treated eyes (26.2% versus 16.9%, $p < 0.001$), which is likely explained by the adherence issue affecting medical but not laser therapy.⁵⁷

The COAST research team believes strongly that the LiGHT study's results, and the effect of its publication on raising the level of discourse regarding the role of SLT in glaucoma management, will lead

to a paradigm shift in which SLT becomes the preferred first-line therapy for glaucoma. We designed the COAST trial to optimize SLT technique so as to optimize clinical outcomes.

The Case For Low Energy SLT

Standard SLT Causes TM Damage. The energy level at which trabeculoplasty has been performed has evolved over time and may not yet be optimized. ALT used a high-energy argon laser platform and consisted of ~80-100 treatment spots spaced ~4 spot widths apart through the full 360° of trabecular meshwork (TM) or 40-50 spots over 180°. ⁵⁸ ALT caused focal coagulative and contractile destruction of TM and presumably lowered IOP by indirect effects on untreated intervening TM tissue through mechanical, biochemical, and/or cellular mechanisms. ^{59,60} Cumulative TM damage ultimately compromised IOP control with repeat ALT as a critical mass of TM was destroyed and too little intervening TM remained to permit aqueous outflow. In fact, repeat ALT sometimes produced paradoxical IOP elevations (presumably due to cumulative coagulative damage to the trabecular outflow pathway ⁶¹) that often required surgical intervention. ⁶²⁻⁶⁷ On this basis, repeat ALT was not incorporated into the GLT study design: when additional IOP reduction was required in laser-first eyes, medical therapy was initiated. ⁶⁸

SLT uses the Q-switched, frequency-doubled Nd:YAG laser platform and consists of ~100 contiguous nonoverlapping treatment spots over the full 360° of TM. Now 2 decades after its commercialization, SLT is almost exclusively performed as first described by Latina and colleagues in 1998: beginning at 0.8 mJ, energy is titrated during the first few treatment spots to the lowest setting that still produces champagne-sized cavitation bubbles, then reduced by a further 0.1 mJ for the remaining treatment. ⁶⁹ This now-standard approach is based not on the optimal balance of efficacy and safety as might be derived from traditional clinical dose-response studies, but rather was described based on observations of optimal laser energy absorption by cultured TM cells *in vitro*. ⁷⁰ The energy fluence delivered with SLT is several thousand times less than with ALT, which reduces but does not eliminate coagulative damage to the meshwork tissue. ^{61,71-73} Kramer and Noecker reported that while SLT caused far less damage to the TM than ALT, there was nevertheless ultrastructural evidence of laser-tissue interaction that included cracking of intracytoplasmic pigment granules and disruption of trabecular endothelial cells in eye bank eyes. ⁶¹ Wood and colleagues demonstrated in cultured bovine TM cells that SLT in the standard energy range (0.75-1.0 mJ) caused rapid necrotic cell death within 1-8 hours and delayed apoptotic cell death within 2-3 days after laser irradiation. ⁷¹ In three human eyes scheduled for unrelated enucleation, histologic damage to the TM was also documented following SLT at standard energy (mean 0.7 mJ/spot) that was identical in nature to, but less severe than, the damage produced by ALT: TM cell disorganization and fragmentation, trabecular beam disruption, and tissue debris in the intertrabecular spaces. ⁷² In human cadaver eyes treated with SLT at a range of energy, transmission electron microscopy revealed disrupted TM cells with cracked and extracellular pigment granules; at higher SLT energy, scanning electron microscopy revealed TM destruction with scrolling of trabecular beams. ⁷³ These findings have led researchers to question whether the “champagne bubble” tissue endpoint represents optimal care and postulated a role for low energy SLT. ⁷⁴

Safety Issues With Standard SLT. While SLT is generally considered a safe procedure, postoperative complications can occur. Transient anterior chamber inflammation is common (incidence 30-83%) but typically resolves quickly without sequelae. ^{38,49,69,75,76} Post-laser IOP spikes occur in up to 27% of eyes. ^{38,49,69,77} However, this appears to be far less common when SLT is performed as primary therapy; in the LiGHT study, only a single case—out of 776 SLT treatments—experienced and IOP spike necessitating medical therapy. ¹⁶ Vision-threatening complications of SLT are exceedingly rare. Recently, several case reports and small case series have identified a variety of potentially vision-threatening corneal complications of SLT. These include short-term reductions in endothelial cell density, ⁷⁸ corneal edema (in up to 0.8% of treated eyes ⁷⁹) complicated in some cases by irregular astigmatism, decompensation, and permanent reduction in visual acuity, ⁸⁰⁻⁸⁵ keratitis, ^{86,87} and corneal thinning with permanent hyperopia shifts of up to 6D. ^{82,84}

Evidence For An SLT Dose-Response Relationship. Can SLT be performed at a lower energy level and still deliver the efficacy achieved at standard energy? Several studies seeking to identify factors associated with success/failure of SLT have included measures of laser dose (total energy, number of spots, energy per spot, etc.) and have generally found no evidence for a dose-response effect on IOP reduction.⁸⁸⁻⁹¹ These studies are limited, however, in that each study delivered standard SLT in all eyes, and standard SLT is performed in such a way as to eliminate a dose-response relationship. A dose-response relationship exists when a heterogeneous array of doses produces a heterogeneous array of responses that are related non-randomly. In standard SLT, a heterogeneous dose of energy is *administered* to the TM but is titrated to produce a standardized tissue response (champagne-like cavitation bubbles) which in turn likely represents a homogenous dose of energy *absorbed* by the tissue. Thus, standard SLT produces a homogenous dose at the tissue level. This is akin to adjusting systemic gentamicin dosing by body weight to achieve consistent therapeutic serum drug concentrations—a heterogeneous dose is administered but a homogenous tissue-level dose is achieved. This approach, in fact, is designed to *negate* a dose-response relationship.

Comparative studies varying the extent of angle treated with SLT have produced mixed results. Two randomized clinical trials (RCTs) demonstrated that 90°⁹² and 180°⁹³ of standard SLT produced similar efficacy to 360° standard SLT, while a third RCT showed a dose-response effect with greater IOP reductions but commensurately more pain, inflammation, and IOP spikes when more angle was treated.³⁸ Retrospective studies have also shown limited efficacy with 180° treatment compared to 360° treatment.⁹⁴⁻⁹⁷ Placing 100 treatment spots over 180° had twice the failure rate of standard 50 spots/180° in a retrospective study, demonstrating that more is not necessarily better.⁹⁸

Few studies have specifically compared multiple energy levels directly in head-to-head fashion. Wong and colleagues retrospectively evaluated outcomes of SLT performed before and after a practice pattern change in which eyes received 120 spots (before) or 160 spots (after) of standard energy 360° SLT; mean IOP and survival at target IOP were statistically similar between groups, indicating no perceptible benefit to higher total energy delivered.⁹⁹ It has been suggested that a lower-energy laser would likely reduce the adverse event profile of SLT with minimal impact on efficacy.¹⁰⁰ Two prospective trials compared standard SLT to lower energy SLT. Zhang and colleagues compared standard SLT to SLT performed at 2/3 of standard energy (but failed to define how this low energy level was established for each eye).¹⁰¹ No differences in mean IOP were seen at 12 months in this single-site study with no *a priori* power/sample size analysis. Tang and colleagues prospectively compared standard and ½ standard energy SLT (again not describing what constituted ½ of standard energy for each eye) and found similar mean IOP reduction between groups but fewer adverse events in the low-energy group.¹⁰² The reduction in adverse events with lower energy is consistent with the findings of a study of variable SLT energy (0.05 – 1.0 mJ) applied to cultured trabecular meshwork cells that found no histological evidence of cell damage at energies below 0.75 mJ,⁷¹ and also to a similar study that found no morphological changes or alterations in expression of apoptosis or necrosis genes at <0.5 mJ.¹⁰³

These studies have a number of significant limitations. Most are retrospective, uncontrolled, conducted at single centers by single surgeons, have small sample sizes with no *a priori* hypotheses or power and sample size calculations, and most combine primary and adjunctive SLT cases. However, while not definitive due to their limitations, the results of these studies cumulatively suggest that energy above standard SLT energy does not improve efficacy but does increase the risk of adverse events, while energy below standard SLT energy provides comparable IOP reduction while also reducing the rate of adverse events.

The Case For Annual Low Energy Repeat SLT

Cumulative Damage With Repeat SLT. The efficacy and safety of repeat SLT—at least to the extent that a single repeat SLT is performed—have now been definitively established.⁸⁻¹⁶ In the context of an SLT-based approach to long-term management of POAG, consisting of primary SLT repeated as needed, there may be an upper limit to the number of times SLT can be repeated⁸ before cumulative TM damage from

both the underlying glaucoma process and multiple SLT treatments reduces TM responsivity to further SLT treatment.

Preserve Versus Rescue. The pathogenesis of glaucoma includes impairment of TM function with reduction in cellularity, reducing trabecular outflow facility and raising IOP. The overall mechanism by which SLT lowers IOP is by increasing outflow facility and thus increasing aqueous egress from the eye via the trabecular outflow pathway.¹⁰⁴ The tissue-level mechanism of action of SLT is incompletely characterized and includes contributions from cytokine secretion, matrix metalloproteinase induction, increased cell division, repopulation of burn sites, and macrophage recruitment.¹⁰⁵ Alterations in both TM and Schlemm's canal endothelial cells (TMEs and SCEs) may mediate trabecular outflow enhancement after SLT. Laser irradiation of TMEs and SCEs induced upregulation of various cytokine genes; direct SCE irradiation is not necessary, however, as exposure of SCEs to media conditioned by irradiated TMEs (as would occur post-SLT *in vivo* as TME effluent washes downstream into Schlemm's canal) also upregulates cytokine genes in SCEs.¹⁰⁶ In response to this increased cytokine exposure, SCEs become more permeable, which may enhance aqueous egress through the trabecular outflow pathway and contribute to IOP reduction.^{107,108} Further, monocytes are recruited to the TM following SLT in quantities 4- to 5-fold higher than usual, and infusion of autologous monocytes into the anterior chamber of rabbits increases outflow facility 2-fold in a rapid and sustained manner.¹⁰⁹

In the setting of TM impairment from glaucoma with elevated IOP, SLT can be considered to rescue impaired TM cell function and restore aqueous outflow through the trabecular pathway, lowering IOP. As SLT does not affect the underlying glaucoma disease process, glaucoma-related TM impairment recurs over time, manifested clinically as IOP elevation over time. Repeat SLT may again rescue impaired TM cells, once again improving trabecular outflow and lowering IOP. There is likely a finite number of such cycles the TM can go through before cumulative TM tissue damage both from the underlying glaucoma disease process and from coagulative SLT effects limits subsequent TM responsiveness to subsequent SLT. In seeking a strategy to optimize and extend patients' responsivity to SLT over time, with the goal of extending medication-free survival, Gandolfi's preliminary clinical work supports the hypothesis that low energy SLT may increase the possible number of such cycles by minimizing the cumulative TM damage caused by SLT. But a vital question remains unanswered: would it be advantageous to deliver low energy repeat SLT annually, regardless of IOP, to *preserve* TM cells and *maintain* TM health rather than await glaucomatous TM re-impairment before *rescuing* impaired TM cells? This approach is analogous to the management of neovascular age-related macular degeneration with anti-VEGF therapy, which has evolved from PRN retreatment (in which retreatment is administered as rescue therapy only when the prior dose wears off and the macula thickens and/or the visual acuity drops) to treat-and-extend retreatment (in which retreatment is administered before clinical decline to preserve macular health) with the treat-and-extend approach producing better outcomes than the PRN approach because it prevents the recurrent disruption of macular structure and function between each retreatment that incrementally leads to irreversible damage.

Summary and Clinical Relevance

To summarize, we hypothesize in the COAST trial—based on Gandolfi's proof-of-concept study and evidence-based biological plausibility—that low energy SLT, repeated annually irrespective of IOP, may reduce both SLT-related and glaucoma-related cumulative TM damage, thus preserving TM responsivity to SLT and extending the duration of which SLT can maintain glaucoma control and prevent or delay the need for medications or surgery. If our hypothesis is proved correct, the findings would have great significance in the management of our patients with glaucoma. The therapeutic landscape for glaucoma is undergoing an evolutionary renaissance of new drugs, new delivery systems, new lasers, and new surgeries, including MIGS. The glaucoma treatment paradigm will inevitably evolve to embrace these new therapeutic options. It has been estimated that patients live an average of ~15 years after the diagnosis of POAG.¹¹⁰ If we validate an SLT treatment strategy that extends the duration of medication-free disease control, we move one step closer to the possibility of a drop-free lifetime for our patients. Delaying the need for medications by 3, or 5, or 7 years not only confers all the benefits of medication-

freedom during this period (which will be all that many patients would need in their lifetimes)—it also allows time for development of safer and more effective drugs dosed infrequently via sustained-release delivery systems, as well as better surgical options, for patients whose lifespans exceed SLT responsiveness. Thus, a new treatment paradigm consisting of SLT, then sustained-release medications, followed by minimally invasive glaucoma surgery and then—for the few who will progress this far—filtering procedures could offer the majority of glaucoma patients the very real possibility of a drop-free lifetime of therapy. As instruments to measure glaucoma *treatment-related* quality of life are developed and validated, the benefits of freedom from the responsibility and detractions of daily medication self-dosing on our patients' well-being are likely to become apparent as well.

ACCEPTED

References

1. Gandolfi S. Low power selective laser trabeculoplasty (SLT) repeated yearly as primary treatment in open angle glaucoma(s): long term comparison with conventional SLT and ALT. E-Abstract 3459. Association for Research in Vision and Ophthalmology Annual Meeting; May 1, 2018, 2018; Honolulu, HA.
2. The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-Up Study: 7. Results. Glaucoma Laser Trial Research Group. *Am J Ophthalmol*. 1995;120(6):718-731.
3. Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. *Clinical Ophthalmology*. 2016;10:189-206.
4. Agrawal P, Bradshaw SE. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. *Ophthalmol Ther*. 2018;7(1):49-73.
5. Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. *Clin Exp Ophthalmol*. 2017;45(4):393-400.
6. Bovee CE, Pasquale LR. Evolving Surgical Interventions in the Treatment of Glaucoma. *Semin Ophthalmol*. 2017;32(1):91-95.
7. Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. *PLoS One*. 2017;12(8):e0183142.
8. Hutnik C, Crichton A, Ford B, et al. Selective Laser Trabeculoplasty versus Argon Laser Trabeculoplasty in Glaucoma Patients Treated Previously with 360 degrees Selective Laser Trabeculoplasty: A Randomized, Single-Blind, Equivalence Clinical Trial. *Ophthalmology*. 2019;126(2):223-232.
9. Francis BA, Loewen N, Hong B, et al. Repeatability of selective laser trabeculoplasty for open-angle glaucoma. *BMC Ophthalmol*. 2016;16:128.
10. Durr GM, Harasymowycz P. The effect of repeat 360-degree selective laser trabeculoplasty on intraocular pressure control in open-angle glaucoma. *J Fr Ophtalmol*. 2016;39(3):261-264.
11. Polat J, Grantham L, Mitchell K, Realini T. Repeatability of selective laser trabeculoplasty. *Br J Ophthalmol*. 2016;100(10):1437-1441.
12. Khouri AS, Lari HB, Berezina TL, Maltzman B, Fechtner RD. Long term efficacy of repeat selective laser trabeculoplasty. *J Ophthalmic Vis Res*. 2014;9(4):444-448.
13. Khouri AS, Lin J, Berezina TL, Maltzman B, Fechtner RD. Repeat selective laser trabeculoplasty can be effective in eyes with initial modest response. *Middle East Afr J Ophthalmol*. 2014;21(3):205-209.
14. Avery N, Ang GS, Nicholas S, Wells A. Repeatability of primary selective laser trabeculoplasty in patients with primary open-angle glaucoma. *Int Ophthalmol*. 2013;33(5):501-506.
15. Hong BK, Winer JC, Martone JF, Wand M, Altman B, Shields B. Repeat selective laser trabeculoplasty. *J Glaucoma*. 2009;18(3):180-183.
16. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. *Lancet*. 2019;393(10180):1505-1516.
17. Newman-Casey PA, Dayno M, Robin AL. Systematic Review of Educational Interventions to Improve Glaucoma Medication Adherence: an update in 2015. *Expert Rev Ophthalmol*. 2016;11(1):5-20.
18. Newman-Casey PA, Weizer JS, Heisler M, Lee PP, Stein JD. Systematic review of educational interventions to improve glaucoma medication adherence. *Semin Ophthalmol*. 2013;28(3):191-201.
19. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). *Invest Ophthalmol Vis Sci*. 2007;48(11):5052-5057.

20. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. *Ophthalmology*. 2009;116(11 Suppl):S30-36.
21. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. *Curr Opin Ophthalmol*. 2006;17(2):190-195.
22. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. *J Glaucoma*. 2003;12(5):393-398.
23. Muir KW, Lee PP. Glaucoma medication adherence: room for improvement in both performance and measurement. *Arch Ophthalmol*. 2011;129(2):243-245.
24. Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. *Arch Ophthalmol*. 2010;128(3):276-287.
25. Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. *J Glaucoma*. 2012;21(7):460-468.
26. Arora V, Bali SJ, Gupta SK, et al. Impact of initial topical medical therapy on short-term quality of life in newly diagnosed patients with primary glaucoma. *Indian J Ophthalmol*. 2015;63(6):511-515.
27. Balkrishnan R, Bond JB, Byerly WG, Camacho FT, Anderson RT. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a medicare health maintenance organization. *Am J Geriatr Pharmacother*. 2003;1(2):75-81.
28. Gupta V, Dutta P, Ov M, Kapoor KS, Sihota R, Kumar G. Effect of glaucoma on the quality of life of young patients. *Invest Ophthalmol Vis Sci*. 2011;52(11):8433-8437.
29. Basilio AL, Moura-Coelho N, Passos I, et al. XEN((R)) implant and trabeculectomy medium-term quality of life assessment and comparison of results. *Int J Ophthalmol*. 2018;11(12):1941-1944.
30. American Academy of Ophthalmology. *Primary open-angle glaucoma: Preferred Practice Pattern*. San Francisco: American Academy of Ophthalmology; 2015.
31. European Glaucoma Society. *Terminology and Guidelines for Glaucoma*. 4th Edition. In. Savona, Italy: PubliComm; 2014.
32. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. *Cornea*. 2010;29(6):618-621.
33. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. *J Glaucoma*. 2008;17(5):350-355.
34. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: The good, the bad and the ugly. *Prog Retin Eye Res*. 2010.
35. Wittenborn JS, Rein DB. Cost-effectiveness of glaucoma interventions in Barbados and Ghana. *Optom Vis Sci*. 2011;88(1):155-163.
36. Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. *Arch Ophthalmol*. 2012;130(4):497-505.
37. McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. *J Glaucoma*. 2006;15(2):124-130.
38. Nagar M, Ogunyomade A, O'Brart DP, Howes F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. *Br J Ophthalmol*. 2005;89(11):1413-1417.
39. Realini T, Shillingford-Ricketts H, Burt D, Balasubramani GK. West Indies Glaucoma Laser Study (WIGLS): 1. 12-Month Efficacy of Selective Laser Trabeculoplasty in Afro-Caribbeans With Glaucoma. *Am J Ophthalmol*. 2017;184:28-33.
40. Realini T. Selective laser trabeculoplasty for the management of open-angle glaucoma in St. Lucia. *JAMA Ophthalmol*. 2013;131(3):321-327.
41. Ouattara OAS, Coulibaly F, Ouffoue YG, et al. [Selective laser trabeculoplasty in African blacks]. *J Fr Ophthalmol*. 2019;42(1):44-48.

42. Goosen E, Coleman K, Visser L, Sponsel WE. Racial Differences in Selective Laser Trabeculoplasty Efficacy. *J Curr Glaucoma Pract.* 2017;11(1):22-27.
43. Seck SM, Agboton G, Dieng M, et al. [Selective laser trabeculoplasty (SLT): our experience in African blacks]. *J Fr Ophtalmol.* 2015;38(3):238-246.
44. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology.* 2014;121(11):2081-2090.
45. Bourne RR, Taylor HR, Flaxman SR, et al. Number of People Blind or Visually Impaired by Glaucoma Worldwide and in World Regions 1990 - 2010: A Meta-Analysis. *PLoS ONE.* 2016;11(10):e0162229.
46. Realini T. Five Years' Experience with Selective Laser Trabeculoplasty in St. Lucia. European Glaucoma Society Annual Meeting; June 2016, 2016; Prague, Czech Republic.
47. Realini T. Selective laser trabeculoplasty: a review. *J Glaucoma.* 2008;17(6):497-502.
48. Song J. Complications of selective laser trabeculoplasty: a review. *Clin Ophthalmol.* 2016;10:137-143.
49. Damji KF, Shah KC, Rock WJ, Bains HS, Hodge WG. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. *Br J Ophthalmol.* 1999;83(6):718-722.
50. Popiela G, Muzyka M, Szelepin L, Cwirko M, Nizankowska MH. [Use of YAG-Selecta laser and argon laser in the treatment of open angle glaucoma]. *Klin Oczna.* 2000;102(2):129-133.
51. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, et al. Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain. *Eye.* 2004;18(5):498-502.
52. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial. *Br J Ophthalmol.* 2006;90(12):1490-1494.
53. Best UP, Domack H, Schmidt V. [Pressure reduction after selective laser trabeculoplasty with two different laser systems and after argon laser trabeculoplasty - a controlled prospective clinical trial on 284 eyes.]. *Klin Monatsbl Augenheilkd.* 2007;224(3):173-179.
54. Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. *Ophthalmology.* 2004;111(10):1853-1859.
55. Van de Veire S, Zeyen T, Stalmans I. Argon versus selective laser trabeculoplasty. *Bull Soc Belge Ophtalmol.* 2006(299):5-10.
56. Garg A, Vickerstaff V, Nathwani N, et al. Primary Selective Laser Trabeculoplasty for Open Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success and Safety from the Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. *Ophthalmology.* 2019 (in press).
57. Wright DM, Konstantakopoulou E, Montesano G, et al. Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) *Ophthalmology.* 2020;127(10):1313-1321.
58. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. *Arch Ophthalmol.* 1979;97(2):319-322.
59. Van Buskirk EM. Pathophysiology of laser trabeculoplasty. *Surv Ophthalmol.* 1989;33(4):264-272.
60. Stein JD, Challa P. Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty. *Curr Opin Ophthalmol.* 2007;18(2):140-145.
61. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. *Ophthalmology.* 2001;108(4):773-779.

62. Grayson DK, Camras CB, Podos SM, Lustgarten JS. Long-term reduction of intraocular pressure after repeat argon laser trabeculoplasty. *Am J Ophthalmol*. 1988;106(3):312-321.
63. Rouhiainen H, Terasvirta M. Repeated 50 burn/180 degree argon laser trabeculoplasty. *Acta Ophthalmol (Copenh)*. 1988;66(1):83-86.
64. Messner D, Siegel LI, Kass MA, Kolker AE, Gordon M. Repeat argon laser trabeculoplasty. *Am J Ophthalmol*. 1987;103(1):113-115.
65. Bergea B. Repeated argon laser trabeculoplasty. *Acta Ophthalmol (Copenh)*. 1986;64(3):246-250.
66. Starita RJ, Fellman RL, Spaeth GL, Poryzees E. The effect of repeating full-circumference argon laser trabeculoplasty. *Ophthalmic Surg*. 1984;15(1):41-43.
67. Hugkulstone CE. Standard and long duration repeat argon laser trabeculoplasty. *Acta Ophthalmol (Copenh)*. 1990;68(5):575-578.
68. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. *Ophthalmology*. 1990;97(11):1403-1413.
69. Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. *Ophthalmology*. 1998;105(11):2082-2088; discussion 2089-2090.
70. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. *Exp Eye Res*. 1995;60(4):359-371.
71. Wood JP, Plunkett M, Previn V, Chidlow G, Casson RJ. Rapid and delayed death of cultured trabecular meshwork cells after selective laser trabeculoplasty. *Lasers Surg Med*. 2010;42(4):326-337.
72. Cvenkel B, Hvala A, Drnovsek-Olup B, Gale N. Acute ultrastructural changes of the trabecular meshwork after selective laser trabeculoplasty and low power argon laser trabeculoplasty. *Lasers Surg Med*. 2003;33(3):204-208.
73. SooHoo JR, Seibold LK, Ammar DA, Kahook MY. Ultrastructural Changes in Human Trabecular Meshwork Tissue after Laser Trabeculoplasty. *J Ophthalmol*. 2015;2015:476138.
74. SooHoo JR, Seibold LK, Kahook MY. Dogma vs Data: Using "Champagne Bubbles" to Titrate SLT Power. *Glaucoma Physician*. 2019;23:32-34.
75. Realini T, Shillingford-Ricketts H, Burt D, Balasubramani GK. West Indies Glaucoma Laser Study (WIGLS) 3. Anterior Chamber Inflammation Following Selective Laser Trabeculoplasty in Afro-Caribbeans with Open-Angle Glaucoma. *J Glaucoma*. 2019.
76. Realini T, Charlton J, Hettlinger M. The impact of anti-inflammatory therapy on intraocular pressure reduction following selective laser trabeculoplasty. *Ophthalmic Surg Lasers Imaging*. 2010;41(1):100-103.
77. Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. *Clin Exp Ophthalmol*. 2004;32(4):368-372.
78. Lee JW, Chan JC, Chang RT, et al. Corneal changes after a single session of selective laser trabeculoplasty for open-angle glaucoma. *Eye (Lond)*. 2014;28(1):47-52.
79. Latina MA, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. *Curr Opin Ophthalmol*. 2002;13(2):94-96.
80. Liu ET, Seery LS, Arosemena A, Lamba T, Chaya CJ. Corneal edema and keratitis following selective laser trabeculoplasty. *Am J Ophthalmol Case Rep*. 2017;6:48-51.
81. Wood SD, Elam A, Moroi S. Rare corneal complication following selective laser trabeculoplasty. *Am J Ophthalmol Case Rep*. 2018;10:28-31.
82. Knickelbein JE, Singh A, Flowers BE, et al. Acute corneal edema with subsequent thinning and hyperopic shift following selective laser trabeculoplasty. *J Cataract Refract Surg*. 2014;40(10):1731-1735.
83. Ozkok A, Tamcelik N, Ucar Comlekoglu D, Iskeleli G. Corneal decompensation after selective laser trabeculoplasty. *Case Rep Ophthalmol Med*. 2014;2014:851971.
84. Regina M, Bunya VY, Orlin SE, Ansari H. Corneal edema and haze after selective laser trabeculoplasty. *J Glaucoma*. 2011;20(5):327-329.

85. Moubayed SP, Hamid M, Choremis J, Li G. An unusual finding of corneal edema complicating selective laser trabeculoplasty. *Can J Ophthalmol*. 2009;44(3):337-338.
86. Chadha N, Belyea DA, Grewal S. Herpetic Stromal Keratitis following Selective Laser Trabeculoplasty. *Case Rep Ophthalmol Med*. 2016;2016:5768524.
87. Holz H, Pirouzian A. Bilateral diffuse lamellar keratitis following consecutive selective laser trabeculoplasty in LASIK patient. *J Cataract Refract Surg*. 2010;36(5):847-849.
88. Ayala M, Chen E. Predictive factors of success in selective laser trabeculoplasty (SLT) treatment. *Clin Ophthalmol*. 2011;5:573-576.
89. Habib L, Lin J, Berezina T, Holland B, Fechtner RD, Khouri AS. Selective laser trabeculoplasty: Does energy dosage predict response? *Oman J Ophthalmol*. 2013;6(2):92-95.
90. Mao AJ, Pan XJ, McIlraith I, Strasfeld M, Colev G, Hutnik C. Development of a prediction rule to estimate the probability of acceptable intraocular pressure reduction after selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension. *J Glaucoma*. 2008;17(6):449-454.
91. Hodge WG, Damji KF, Rock W, Buhrmann R, Bovell AM, Pan Y. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. *Br J Ophthalmol*. 2005;89(9):1157-1160.
92. Tawfique K, Khademi P, Querat L, Khadamy J, Chen E. Comparison between 90-degree and 360-degree selective laser trabeculoplasty (SLT): A 2-year follow-up. *Acta Ophthalmol*. 2019;97(4):427-429.
93. Goyal S, Beltran-Agullo L, Rashid S, et al. Effect of primary selective laser trabeculoplasty on tonographic outflow facility: a randomised clinical trial. *Br J Ophthalmol*. 2010;94(11):1443-1447.
94. Shibata M, Sugiyama T, Ishida O, et al. Clinical results of selective laser trabeculoplasty in open-angle glaucoma in Japanese eyes: comparison of 180 degree with 360 degree SLT. *J Glaucoma*. 2012;21(1):17-21.
95. Prasad N, Murthy S, Dagianis JJ, Latina MA. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension. *J Glaucoma*. 2009;18(2):157-160.
96. Song J, Lee PP, Epstein DL, et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. *J Glaucoma*. 2005;14(5):400-408.
97. Chen E, Golchin S, Blomdahl S. A comparison between 90 degrees and 180 degrees selective laser trabeculoplasty. *J Glaucoma*. 2004;13(1):62-65.
98. George MK, Emerson JW, Cheema SA, et al. Evaluation of a modified protocol for selective laser trabeculoplasty. *J Glaucoma*. 2008;17(3):197-202.
99. Wong C, Tao LW, Skalicky SE. A Retrospective Review Comparing the Safety and Efficacy of 120 Versus 160 Applications of Selective Laser Trabeculoplasty. *J Glaucoma*. 2018;27(1):94-99.
100. Paiva ACM, da Fonseca AS. Could adverse effects and complications of selective laser trabeculoplasty be decreased by low-power laser therapy? *Int Ophthalmol*. 2019;39(1):243-257.
101. Zhang HY, Qin YJ, Yang YF, Xu JG, Yu MB. Intraocular Pressure-Lowering Potential of Subthreshold Selective Laser Trabeculoplasty in Patients with Primary Open-Angle Glaucoma. *J Ophthalmol*. 2016;2016:2153723.
102. Tang M, Fu Y, Fu MS, et al. The efficacy of low-energy selective laser trabeculoplasty. *Ophthalmic Surg Lasers Imaging*. 2011;42(1):59-63.
103. Izzotti A, Longobardi M, Cartiglia C, Rathschuler F, Sacca SC. Trabecular meshwork gene expression after selective laser trabeculoplasty. *PLoS One*. 2011;6(7):e20110.
104. Gulati V, Fan S, Gardner BJ, et al. Mechanism of Action of Selective Laser Trabeculoplasty and Predictors of Response. *Invest Ophthalmol Vis Sci*. 2017;58(3):1462-1468.
105. Kagan DB, Gorfinkel NS, Hutnik CM. Mechanisms of selective laser trabeculoplasty: a review. *Clin Exp Ophthalmol*. 2014;42(7):675-681.

106. Alvarado JA, Chau P, Wu J, Juster R, Shifera AS, Geske M. Profiling of Cytokines Secreted by Conventional Aqueous Outflow Pathway Endothelial Cells Activated In Vitro and Ex Vivo With Laser Irradiation. *Invest Ophthalmol Vis Sci.* 2015;56(12):7100-7108.
107. Alvarado JA, Iguchi R, Martinez J, Trivedi S, Shifera AS. Similar effects of selective laser trabeculoplasty and prostaglandin analogs on the permeability of cultured Schlemm canal cells. *Am J Ophthalmol.* 2010;150(2):254-264.
108. Alvarado JA, Iguchi R, Juster R, Chen JA, Shifera AS. From the bedside to the bench and back again: predicting and improving the outcomes of SLT glaucoma therapy. *Trans Am Ophthalmol Soc.* 2009;107:167-181.
109. Alvarado JA, Katz LJ, Trivedi S, Shifera AS. Monocyte modulation of aqueous outflow and recruitment to the trabecular meshwork following selective laser trabeculoplasty. *Arch Ophthalmol.* 2010;128(6):731-737.
110. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. *Invest Ophthalmol Vis Sci.* 1997;38(1):83-91.

ACCEPTED